Serum Potassium and Cardiovascular Events in Heart Failure with Preserved Left Ventricular Ejection Fraction Patients.

Link to article at PubMed

Serum Potassium and Cardiovascular Events in Heart Failure with Preserved Left Ventricular Ejection Fraction Patients.

Am J Hypertens. 2018 Jul 07;:

Authors: Nishihara T, Tokitsu T, Sueta D, Takae M, Oike F, Fujisue K, Usuku H, Takashio S, Hanatani S, Kanazawa H, Arima Y, Sakamoto K, Izumiya Y, Yamabe H, Kaikita K, Yamamoto E, Tsujita K

Abstract
Background: Although serum potassium (sK) levels are closely associated with the prognosis of chronic heart failure patients, the clinical significance of sK levels in cardiovascular outcomes of heart failure with preserved ejection fraction (HFpEF) patients is not fully understood.
Methods: This study was a retrospective, single-center, observational study. We enrolled 506 consecutive HFpEF patients admitted to Kumamoto University Hospital and divided them into four groups according to the quartiles of the sK levels at discharge (Q1; sK < 4.1 mEq/L, Q2; 4.1 ≤ sK < 4.4 mEq/L, Q3; 4.4 ≤ sK < 4.7 mEq/L, and Q4; sK ≥ 4.7 mEq/L).
Results: No significant differences were observed in the use of all drugs (loop diuretics, mineralocorticoid receptor antagonists, renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, β-blockers and statins) among the 4 groups. Hemoglobin, the estimated glomerular filtration rate and pulse wave velocity levels were lower and the serum sodium levels were higher in the Q4 group compared to those in the Q2 group. Kaplan-Meier analysis revealed significantly higher probabilities of both cardiovascular and HF-related events in the Q1, Q3 and Q4 groups than those in the Q2 group. Multivariate Cox-proportional-hazard analysis revealed that the Q1, Q3 and Q4 groups had significantly and independently higher probabilities of cardiovascular events compared with those in the Q2 group, indicating a J-shaped association between sK levels and cardiovascular events.
Conclusions: sK levels at discharge could provide important prognostic information in regard to HFpEF. Further evaluation in a larger number of patients might be needed.

Clinical Trial Registration: UMIN-CTR (http://www.umin.ac.jp/ctr/). Identifier: UMIN000029600.

PMID: 29985986 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.